Fig. 3 | npj Systems Biology and Applications

Fig. 3

From: Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations

Fig. 3

Validation of whole-body PBPK models. Simulated plasma concentration-time curves (lines) are assessed with experimental PK profiles (circles) for a diclofenac (DFN = blue, 4’-OH-DFN = red, 5-OH-DFN = green, 3’-OH-DFN = yellow, DFN-AGLU = purple), b celecoxib (CEL = blue, OH-CEL = red, COOH-CEL = green), c zileuton (ZLT = blue, ZLT-GLU = red, ZLT-SO = green, OH-ZLT = yellow, d licofelone (LCF = blue, LCF-AGLU = red, OH-LCF = green, and e rifampicin (RIF = blue, DA-RIF = red). Renal excretion rates are simulated for celecoxib, diclofenac, licofelone, and rifampicin (dotted blue lines). In case of rifampicin, biliary excretion rates are additionally presented (dashed blue lines). References, dose levels and administration routes (iv and po) of the experimental data are shown above each plot. In case of several administered doses displayed in the same plot, correspondent simulations are presented in ascending order from light blue to dark blue. Diclofenac, DFN; hydroxy, OH; acyl glucuronide, AGLU; celecoxib, CEL; carboxy, COOH; glucuronide, GLU; zileuton, ZLT; sulfoxide, SO; licofelone, LCF; rifampicin, RIF; desacetyl, DA; zero, one, two 2C9*3, CYP2C9 genotypes

Back to article page